相似文献
1
The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective.
J Infect Dis. 2020 Mar 5;221(Suppl 1):S109-S112. doi: 10.1093/infdis/jiz389.
2
[Cytomegalovirus infection in transplant recipients].
Nihon Rinsho. 1998 Jan;56(1):173-8.
3
Management of cytomegalovirus infection in solid organ transplantation.
Nat Rev Nephrol. 2010 Dec;6(12):711-21. doi: 10.1038/nrneph.2010.141. Epub 2010 Oct 26.
4
Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.
Clin Microbiol Rev. 2020 Oct 28;34(1). doi: 10.1128/CMR.00043-19. Print 2020 Dec 16.
5
Antiviral treatment of cytomegalovirus infection.
Infect Disord Drug Targets. 2011 Oct;11(5):475-503. doi: 10.2174/187152611797636640.
6
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Clin Infect Dis. 2008 Sep 1;47(5):702-11. doi: 10.1086/590934.
7
Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Expert Rev Anti Infect Ther. 2011 Nov;9(11):955-65. doi: 10.1586/eri.11.116.
8
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.
Clin Microbiol Rev. 2000 Jan;13(1):83-121, table of contents. doi: 10.1128/CMR.13.1.83.
9
Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
Clin Transplant. 2019 Sep;33(9):e13512. doi: 10.1111/ctr.13512. Epub 2019 Mar 28.
10
Cytomegalovirus infection in organ transplant recipients.
Infect Dis Clin North Am. 1995 Dec;9(4):863-77.
引用本文的文献
1
Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.
Virol J. 2024 Sep 30;21(1):236. doi: 10.1186/s12985-024-02511-x.
2
Inhibition of Cytomegalovirus by Fucosylated Chondroitin Sulfate Depends on Its Molecular Weight.
Viruses. 2023 Mar 28;15(4):859. doi: 10.3390/v15040859.
3
The establishment of a cytomegalovirus -specific CD8 T-cell threshold by kinetic modeling for the prediction of post-hemopoietic stem cell transplant reactivation.
iScience. 2022 Oct 12;25(11):105340. doi: 10.1016/j.isci.2022.105340. eCollection 2022 Nov 18.
4
Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation.
Front Cell Infect Microbiol. 2022 Aug 3;12:954420. doi: 10.3389/fcimb.2022.954420. eCollection 2022.
5
Human cytomegalovirus infection among treatment-naive HIV-1 infected patients in Ethiopia.
PLoS One. 2021 Feb 18;16(2):e0247264. doi: 10.1371/journal.pone.0247264. eCollection 2021.
本文引用的文献
1
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Clin Infect Dis. 2020 Apr 10;70(8):1525-1533. doi: 10.1093/cid/ciz490.
2
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
3
Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis.
Clin Infect Dis. 2018 Feb 1;66(4):617-631. doi: 10.1093/cid/cix793.
4
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
Clin Infect Dis. 2017 Jan 1;64(1):87-91. doi: 10.1093/cid/ciw668. Epub 2016 Sep 28.
5
Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples.
Clin Infect Dis. 2016 Sep 1;63(5):583-9. doi: 10.1093/cid/ciw370. Epub 2016 Jun 15.
6
A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology.
Biologicals. 2016 Jul;44(4):242-251. doi: 10.1016/j.biologicals.2016.04.005. Epub 2016 May 11.
7
Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.
Lancet Haematol. 2016 Mar;3(3):e119-27. doi: 10.1016/S2352-3026(15)00289-6. Epub 2016 Feb 20.
8
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.
Clin Microbiol Rev. 2013 Oct;26(4):703-27. doi: 10.1128/CMR.00015-13.
9
Direct and indirect effects of cytomegalovirus: can we prevent them?
Enferm Infecc Microbiol Clin. 2010 Jan;28(1):1-5. doi: 10.1016/j.eimc.2009.07.008. Epub 2009 Dec 21.
10
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant. 2007 Sep;7(9):2106-13. doi: 10.1111/j.1600-6143.2007.01910.x. Epub 2007 Jul 19.
Zotero 插件